Phase 3 Readout~month

Phase 3 Topline: Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice

Name: Phase 3 Topline: Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice
Start: 2028-06-01

June 1, 2028

Company: BriaCell Therapeutics Corp. (BCTX)
Drug: bria-imt
Indication: Breast Cancer; Metastatic Breast Cancer; Breast Cancer Metastatic

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice — BCTX Phase 3 Readout | BioSniper